Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics today released preliminary fourth quarter financial results for its RosettaGX Reveal thyroid nodule assay, reporting a 38 percent increase in test sales over the third quarter.

For the three-month period ended Dec. 31, Reveal generated preliminary revenues of $390,000 versus $282,000 in the third quarter. During the fourth quarter, Rosetta received 423 orders for the test compared with 305 units received in the previous quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.